Comment on: Acute lymphoblastic leukemia onset in a 3‐year‐old child with COVID‐19

Colaiacovo, Marie-Laure; Dakhallah, Nawar; Jimenez-Cortes, Camille; Souza, Amalia; Ah-Yan, Christophe; Bernier, Pascal; Bittencourt, Henrique; Laverdière, Caroline; Leclerc, Jean‐Marie; Tran, Thai Hoa

doi:10.1002/pbc.28727

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a few cases presented ALL onset with concomitant Covid-19, and it is still debated whether to start chemotherapy before or after Covid-19 resolution. While some authors reported their experience without chemotherapy delay nor Covid-19 treatment ( 6 ), others postponed chemotherapy or associated it with antiviral therapy ( 7 – 9 ).…”

Section: Introductionmentioning

confidence: 99%

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

et al. 2021

View full text Add to dashboard Cite

Introduction: The spread of Covid-19 has worsened the prognosis of oncology patients, interrupting or delaying life-saving therapies and contextually increasing the risk of severe SARS-CoV-2 infections. Acute lymphoblastic leukemia (ALL) is the most frequent cancer in pediatric age and the management of this disease with concomitant SARS-COV-2 infection represents a challenging situation.Case presentation: We present the case of a 6-year-old female newly diagnosed with ALL during a documented SARS-CoV-2 infection. Our patient was admitted 20 days after SARS-CoV-2 detection for evening-rise fever. Laboratory testing showed severe neutropenia while chest x-ray detected moderate pulmonary involvement. Acute lymphoblastic leukemia diagnosis was made through morphological and molecular analysis on bone marrow aspirate. Given the stability of the blood count and clinical conditions, antiviral therapy with Remdesivir and Convalescent Plasma was started before antileukemic treatment, obtaining a rapid resolution of the infection.Conclusion: In our experience, the treatment with Remdesivir and Convalescent Plasma led to a rapid resolution of Sars-Cov-2 infection. Our case did not present any adverse event to the therapy. Thus, this treatment could be considered in patients with malignancies, in order to accelerate the resolution of the infection and begin immunosuppressive treatment safely. Further studies are required to confirm this hypothesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As these were guidelines developed earlier in the pandemic and with more knowledge and awareness of how COVID-19 affects patients, it is now recommended to begin treatment as soon as feasible, as delaying the induction phase could have an adverse effect on the outcome of the patient [ 60 ]. Further reports have also suggested not delaying treatment, especially as leukemia is curable, and it is noted that pediatric patients typically have a less severe infectious course with COVID-19 [ 61 ] and have shown success in treatment when receiving concurrent care with an active infection from COVID-19 [ 62 ].…”

Section: Management Of Covid-19 In Pediatric Oncologymentioning

confidence: 99%

The Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned

et al. 2023

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected the pediatric oncology population globally. Over the course of 2 years, increasing reports have been made to better understand this entity and its pathologic complications on these patients. The pandemic has allowed healthcare providers, hospital systems, and leading oncologic societies to quickly adapt and formulate new guidelines for the effective understanding, management, and treatment of patients with pediatric malignancy.

show abstract

“…within the timeline as non-COVID ALL. 4 Marcia et al reported a case of 3-year-old boy who had COVID positivity at the time…”

Section: Colaiacovo Et Al Have Recommended Starting Chemotherapymentioning

confidence: 99%

SARS‐CoV‐2 At diagnosis of acute lymphoblastic leukemia—Case series. To worry about COVID or leukemia? A developing country's perspective

Sneha

Tatapudi

Scott

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Comment on: Acute lymphoblastic leukemia onset in a 3‐year‐old child with COVID‐19

Cited by 4 publications

References 6 publications

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

The Impact of COVID-19 on Pediatric Malignancy Diagnosis and Treatment: Never the Same but Lessons Learned

SARS‐CoV‐2 At diagnosis of acute lymphoblastic leukemia—Case series. To worry about COVID or leukemia? A developing country's perspective

Contact Info

Product

Resources

About